Valuation: Immunovia AB

Market Cap 13Cr 1.35Cr 1.18Cr 1.09Cr 1.01Cr 1.92Cr 128.83Cr 1.95Cr 5.07Cr 63Cr 5.08Cr 4.97Cr 218.21Cr P/E 2026 *
-1.94x
P/E 2027 * -4.85x
Enterprise Value 6.35Cr 65.84L 57.55L 52.89L 49.3L 93.51L 63Cr 94.93L 2.47Cr 31Cr 2.47Cr 2.42Cr 106.18Cr EV / Sales 2026 *
19.8x
EV / Sales 2027 * 3.27x
Free-Float
89.3%
Yield 2026 *
-
Yield 2027 * -
1 day-32.03%
1 week+16,507.70%
Current month+16,370.59%
1 month+14,213.90%
3 months+17,042.86%
6 months+13,961.67%
Current year+13,658.62%
1 month 0.18
Extreme 0.1824
0.32
Current year 0.15
Extreme 0.1544
0.32
1 year 0.15
Extreme 0.1544
0.92
3 years 0.15
Extreme 0.1544
2.78
5 years 0.15
Extreme 0.1544
139.14
10 years 0.15
Extreme 0.1544
292
Manager TitleAgeSince
Chief Executive Officer 53 29/04/2023
Chief Tech/Sci/R&D Officer 55 29/04/2024
Chief Tech/Sci/R&D Officer 54 31/01/2024
Director TitleAgeSince
Director/Board Member 72 09/12/2016
Chairman 69 26/05/2023
Director/Board Member 51 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
-32.03%+16,507.70% - - 1.35Cr
+1.46%+2.68%+6.04%-25.89% 1.64TCr
-4.23%+18.28%+39.95%+91.33% 178.4Cr
+1.32%+1.18%-36.88%-77.65% 124.45Cr
-0.31%+3.80%-28.50%+37.99% 113.81Cr
0.00%+4.95%-25.50%-53.00% 64Cr
-2.22%+1.13%-38.00%-57.53% 58Cr
+2.36%+8.67%+29.72%-52.72% 45Cr
-0.32%+0.32%-54.71%-59.44% 38Cr
-2.05%+5.91%-20.77%-20.86% 36Cr
Average -3.52%+7.33%-14.29%-24.20% 254.88Cr
Weighted average by Cap. +0.76%+4.17%+1.67%-18.97%

Financials

2026 *2027 *
Net sales 32L 3L 3L 3L 2L 5L 3.16Cr 5L 12.44L 1.55Cr 12.45L 12.19L 5.35Cr 1.73Cr 17.94L 15.68L 14.41L 13.43L 25.48L 17Cr 25.86L 67.25L 8.4Cr 67.33L 65.88L 29Cr
Net income -9.1Cr -94.35L -82.48L -75.8L -70.65L -1.34Cr -90Cr -1.36Cr -3.54Cr -44Cr -3.54Cr -3.47Cr -152.17Cr -8.2Cr -85.02L -74.32L -68.3L -63.67L -1.21Cr -81Cr -1.23Cr -3.19Cr -40Cr -3.19Cr -3.12Cr -137.12Cr
Net Debt -6.7Cr -69.47L -60.73L -55.81L -52.02L -98.67L -66Cr -1Cr -2.6Cr -33Cr -2.61Cr -2.55Cr -112.04Cr -7.4Cr -76.72L -67.07L -61.64L -57.46L -1.09Cr -73Cr -1.11Cr -2.88Cr -36Cr -2.88Cr -2.82Cr -123.74Cr
Logo Immunovia AB
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Employees
17
Date Price Change Volume
29/26/29 SEK 0.1938 +0.83% 5

Quarterly revenue - Rate of surprise